Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Cambridge Cog (COG) Share Price

Price 35.50p on 18-04-2025 at 04:45:08
Change 0.00p 0%
Buy 37.00p
Sell 34.00p
Buy / Sell COG Shares
Last Trade: Sell 136.00 at 35.20p
Day's Volume: 0
Last Close: 35.50p
Open: 0.00p
ISIN: GB00B8DV9647
Day's Range 0.00p - 0.00p
52wk Range: 26.40p - 52.00p
Market Capitalisation: £15m
VWAP: 0.00p
Shares in Issue: 42m

Cambridge Cog (COG) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 136 35.20p Ordinary
12:57:53 - 17-Apr-25
Sell* 142 35.20p Ordinary
09:30:22 - 17-Apr-25
Sell* 111 34.10p Ordinary
14:00:38 - 16-Apr-25
Sell* 111 34.00p Uncrossing Trade
14:00:22 - 16-Apr-25
Sell* 8,966 34.10p Ordinary
14:33:28 - 15-Apr-25
Sell* 5,000 34.10p Ordinary
14:32:25 - 15-Apr-25
Sell* 3 34.00p SI Trade
12:35:58 - 15-Apr-25
Buy* 1 35.00p SI Trade
12:35:58 - 15-Apr-25
Buy* 14,351 34.84p Ordinary
12:35:41 - 15-Apr-25
Buy* 15 35.00p Ordinary
10:19:07 - 15-Apr-25
See more Cambridge Cog trades

Cambridge Cog (COG) Share Price History

Time period:
to
Date Open High Low Close Volume
18th Apr 2025 (Fri) 35.50 35.50 35.50 35.50 0
17th Apr 2025 (Thu) 35.50 35.50 35.50 35.50 278
16th Apr 2025 (Wed) 34.00 35.50 34.00 35.50 246
15th Apr 2025 (Tue) 34.50 35.50 34.50 35.50 32,841
14th Apr 2025 (Mon) 34.00 35.00 34.50 34.50 18,784
11th Apr 2025 (Fri) 34.00 34.00 34.00 34.00 4,706
10th Apr 2025 (Thu) 34.50 34.50 34.00 34.00 35,038
9th Apr 2025 (Wed) 33.00 33.00 32.00 33.00 1,195
8th Apr 2025 (Tue) 33.00 33.00 32.00 33.00 17,578
7th Apr 2025 (Mon) 33.50 33.50 32.00 33.00 52,796
4th Apr 2025 (Fri) 37.00 37.00 33.50 33.50 62,506
3rd Apr 2025 (Thu) 36.50 37.50 36.50 37.00 45,117
2nd Apr 2025 (Wed) 37.50 37.50 35.50 36.00 83,163
1st Apr 2025 (Tue) 39.00 39.00 37.50 37.50 14,466
31st Mar 2025 (Mon) 39.00 39.00 37.20 39.00 1,935
28th Mar 2025 (Fri) 39.00 39.00 39.00 39.00 5,000
27th Mar 2025 (Thu) 39.00 39.00 39.00 39.00 671
26th Mar 2025 (Wed) 39.00 39.00 39.00 39.00 1,946
25th Mar 2025 (Tue) 39.50 39.50 39.00 39.00 10,498
24th Mar 2025 (Mon) 39.50 40.00 39.50 39.50 538
21st Mar 2025 (Fri) 40.40 40.40 40.00 40.00 28
20th Mar 2025 (Thu) 39.50 40.00 40.00 40.00 14
19th Mar 2025 (Wed) 39.50 40.00 39.00 39.00 3,183
See more Cambridge Cog price history

Cambridge Cog (COG) Regulatory News

Date Source Headline
10th Apr 2025 7:00 am RNS Contract Win
7th Apr 2025 10:24 am RNS Holding(s) in Company
3rd Apr 2025 7:00 am RNS Contract Win
1st Apr 2025 7:00 am RNS Block Listing Return
6th Mar 2025 7:00 am RNS-R CANTAB® used for major global brain health study
18th Feb 2025 7:00 am RNS-R Cambridge Cognition submits FDA Letter of Intent
7th Feb 2025 7:00 am RNS Board Appointment
21st Jan 2025 7:00 am RNS Launch of in-house rater training service
16th Jan 2025 7:00 am RNS Expanded partnership with Actinogen
27th Dec 2024 3:34 pm RNS Director/PDMR Share Purchases
See more Cambridge Cog regulatory news

Cambridge Cog (COG) Share News

TRADING UPDATES: 4Global wins contract; Zeta takes Future Metals stake

10th Apr 2025 20:22

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

TRADING UPDATES: Strategic Minerals sales up; 4Global wins contract

4th Apr 2025 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

AIM WINNERS & LOSERS: Strategic Minerals posts quarterly sales growth

3rd Apr 2025 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

IN BRIEF: Cambridge Cognition extends partnership for Alzheimer's test

17th Jan 2025 07:21

Cambridge Cognition Holdings PLC - Cambridge, England-based brain health software - Expands partnership with Actinogen Medical Ltd for phase 2b/3 XanaMIA Alzheimer's trial. Says Actinogen will continue to utilise Cambridge Cognition's full product suite, leveraging its tools for more precise clinical measurements. Notes that the trial includes 220 patients experiencing Alzheimer's induced dementia, with patients receiving a placebo or emestedastat once daily. The trial intends to show its ability to slow Alzheimer's progression through assessing various endpoints over 36 weeks. Says the ongoing use of Cambridge Cognition's full product suite ensures greater comparability and superior data quality across Actinogen's clinical development programme. Read More

EARNINGS AND TRADING: Dianomi trading in line; Solid State profit dips

10th Dec 2024 15:34

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

See more Cambridge Cog news
FTSE 100 Latest
Value8,275.66
Change0.00

Login to your account

Forgot Password?

Not Registered